GeoVax Labs, Inc. (GOVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Director Effective November 5, 2026, the Board of Directors appointed Shahin Behroyan as a director of the Co
- Person
- Shahin Behroyan
- Title
- director
- Action
- appointed
- Effective
- November 5, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The 8‑K filing provides the first public notice of board and executive changes, a standard corporate governance update for a micro‑cap biotech.
Market read
Governance updates are routine but can affect micro‑cap stock volatility; traders may watch for short‑term price movement.
What to watch
The new director's experience in corporate transactions may enable future partnership or financing opportunities.
Background
GeoVax Labs (GOVX) is a clinical‑stage biotech focused on viral‑vector vaccines and immuno‑oncology therapies.
Ticker impact
SEC Form 8‑K reports appointment of Shahin Behroyan to the board and Tyler O’Brien as interim CEO, a material corporate governance change.
likely modest pressure as investors assess leadership transition; no clear directional catalyst.
The filing is a primary source disclosure of executive changes; such events typically cause short‑term volatility but lack substantive financial impact.
Market effects
Minor; biotech sector may view governance change as routine.
Limited to U.S. over‑the‑counter biotech investors.
Low; no broader market effect.
Counterpoint
Leadership change could signal deeper strategic shifts not yet disclosed, potentially leading to upside if new direction succeeds.
Key entities
- DirectorShahin Behroyan
Appointed to fill vacancy on the board; brings experience in investments and healthcare.
- Interim CEOTyler O’Brien
Assumes chief executive duties and board chairmanship pending permanent appointment.

